目的:通过快速大容量尾静脉注射法建立肝细胞癌小鼠模型。方法:采用快速大容量尾静脉注射法,将插入NRAS基因的NRASV12转座子质粒、表达myr-Akt基因转座子质粒以及转座酶SB100的混合盐溶液通过小鼠尾静脉大容量(2 m L)、短时间(7 s)进行...目的:通过快速大容量尾静脉注射法建立肝细胞癌小鼠模型。方法:采用快速大容量尾静脉注射法,将插入NRAS基因的NRASV12转座子质粒、表达myr-Akt基因转座子质粒以及转座酶SB100的混合盐溶液通过小鼠尾静脉大容量(2 m L)、短时间(7 s)进行注射,作为观察组;同时设置对照组,同样方法注射等量0. 9%氯化钠注射液。注射3~4周后,处死观察组及对照组小鼠,通过病理学检查小鼠成瘤情况。结果:观察组小鼠成瘤率100%(24/24),经病理学检测为肝细胞癌;对照组小鼠无成瘤。结论:快速大容量尾静脉注射方法构建肝细胞癌小鼠模型方法简单,诱癌时间短,成功率高,重复性好。展开更多
Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients (30 men) with SE ...Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients (30 men) with SE treated with IV VPA (average dose, 31.5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration.展开更多
文摘目的:通过快速大容量尾静脉注射法建立肝细胞癌小鼠模型。方法:采用快速大容量尾静脉注射法,将插入NRAS基因的NRASV12转座子质粒、表达myr-Akt基因转座子质粒以及转座酶SB100的混合盐溶液通过小鼠尾静脉大容量(2 m L)、短时间(7 s)进行注射,作为观察组;同时设置对照组,同样方法注射等量0. 9%氯化钠注射液。注射3~4周后,处死观察组及对照组小鼠,通过病理学检查小鼠成瘤情况。结果:观察组小鼠成瘤率100%(24/24),经病理学检测为肝细胞癌;对照组小鼠无成瘤。结论:快速大容量尾静脉注射方法构建肝细胞癌小鼠模型方法简单,诱癌时间短,成功率高,重复性好。
文摘Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients (30 men) with SE treated with IV VPA (average dose, 31.5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration.